NCT06408246View on ClinicalTrials.gov

ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

February 1, 2026

Primary Completion Date

October 1, 2028

Study Completion Date

February 1, 2029

Conditions
Depression
Interventions
DRUG

Guanfacine

Guanfacine immediate release is an established and safe FDA-approved treatment that acts directly by stimulating α2A adrenoceptors.

DRUG

Sertraline

Sertraline is a well-tolerated FDA-approved antidepressant that is among the most widely prescribed medications for depression.

Trial Locations (2)

60607

University of Illinois at Chicago, Chicago

94305

Stanford Psychiatry and Behavioral Sciences Department, Palo Alto

All Listed Sponsors
lead

Stanford University

OTHER